AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17004240 — intervention group
Group type: EXPERIMENTAL
Intervention: RF operators
Number of subjects: 35
Study 17004240 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 35
Study 16309081 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at corresponding acupoints at the healthy side for acute stage (26 cases)
Number of subjects: 79
Study 16309081 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at the affected side with shallow needling method for resting stage (15 cases)
Number of subjects: 79
Study 16309081 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine acupuncture and moxibustion for restoration stage (2 cases)
Number of subjects: 79
Study 16309081 — intervention group
Group type: COMPARATOR
Intervention: Routine acupuncture and moxibustion (control group, 36 cases)
Number of subjects: 79
Study 16309081 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group (all methods combined)
Number of subjects: 79
Study 16309081 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine acupuncture and moxibustion)
Number of subjects: 79
Study 12170406 — intervention group
Group type: EXPERIMENTAL
Intervention: Olympus push enteroscope SIF‐100 (working length 2200 mm)
Number of subjects: 28
Study 12170406 — intervention group
Group type: COMPARATOR
Intervention: Olympus push enteroscope SIF‐Q140 (working length 2500 mm)
Number of subjects: 28
Study 10213294 — intervention group
Group type: EXPERIMENTAL
Intervention: Exosurf
Number of subjects: 0
Study 10213294 — intervention group
Group type: EXPERIMENTAL
Intervention: Survanta
Number of subjects: 0
Study 10213294 — intervention group
Group type: COMPARATOR
Intervention: Control (normal lungs)
Number of subjects: 0
Study 7885264 — intervention group
Group type: EXPERIMENTAL
Intervention: Odd-even status of numbers
Number of subjects: 0
Study 2100986 — intervention group
Group type: EXPERIMENTAL
Intervention: Prism adaptation with augmented surgery
Number of subjects: 188
Study 2100986 — intervention group
Group type: EXPERIMENTAL
Intervention: Prism adaptation with conventional surgery
Number of subjects: 188
Study 2100986 — intervention group
Group type: COMPARATOR
Intervention: No prism adaptation
Number of subjects: 188
Study 2100986 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall effect of prism adaptation
Number of subjects: 188
Study 27127 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg Pindolol (Visken)
Number of subjects: 10
Study 27127 — intervention group
Group type: COMPARATOR
Intervention: Control group (no beta blocker treatment)
Number of subjects: 10
Study 31800462 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 0.1%
Number of subjects: 104
Study 31800462 — intervention group
Group type: EXPERIMENTAL
Intervention: Nepafenac 0.3%
Number of subjects: 104
Study 31800462 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 0.5%
Number of subjects: 104
Study 31800462 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromfenac 0.09%
Number of subjects: 104
Study 31800462 — intervention group
Group type: EXPERIMENTAL
Intervention: Active metabolite amfenac
Number of subjects: 104
Study 31800462 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 104
Study 30906317 — intervention group
Group type: EXPERIMENTAL
Intervention: Deception group
Number of subjects: 15
Study 30906317 — intervention group
Group type: COMPARATOR
Intervention: Honesty group
Number of subjects: 15
Study 28148667 — intervention group
Group type: EXPERIMENTAL
Intervention: Push Ortho Thumb Brace CMC
Number of subjects: 63
Study 28148667 — intervention group
Group type: COMPARATOR
Intervention: Custom-made orthosis
Number of subjects: 63
Study 25514804 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib (≤50 mg daily, monotherapy)
Number of subjects: 69
Study 23616386 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with Dermatophagoides pteronyssinus (D.p.) and Dermatophagoides farina (D.f.) extract (n = 60)
Number of subjects: 120
Study 23616386 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo controls (n = 60)
Number of subjects: 120
Study 22038349 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium bromide inhalation (18 μg/day)
Number of subjects: 127
Study 22038349 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxofylline oral tablets (0.2 g/time, 2 times a day)
Number of subjects: 127
Study 19271232 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric strengthening programme for 8 weeks
Number of subjects: 22
Study 17046260 — intervention group
Group type: EXPERIMENTAL
Intervention: Trip recovery training on a modified treadmill
Number of subjects: 12
Study 17046260 — intervention group
Group type: COMPARATOR
Intervention: Walking on a treadmill for 15 min (Control)
Number of subjects: 12
Study 14722166 — intervention group
Group type: EXPERIMENTAL
Intervention: Management algorithm based on near-patient tests (Hepcon, thromboelastography, PFA-100)
Number of subjects: 102
Study 14722166 — intervention group
Group type: EXPERIMENTAL
Intervention: Management algorithm based on laboratory tests (rapidly available laboratory clotting tests)
Number of subjects: 102
Study 14722166 — intervention group
Group type: COMPARATOR
Intervention: Clinician discretion (retrospective case-control group, n=108)
Number of subjects: 102
Study 11289326 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) aqueous nasal spray, 200 microg for adults and 100 microg for pediatric patients.
Number of subjects: 3605
Study 11289326 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) aqueous nasal spray
Number of subjects: 3605
Study 11289326 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3605
Study 9421852 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous blood transfusion
Number of subjects: 56
Study 9421852 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic blood transfusion
Number of subjects: 56
Study 9421852 — intervention group
Group type: COMPARATOR
Intervention: Nontransfused patients
Number of subjects: 56
Study 7508331 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfuzosin (2.5 mg tid)
Number of subjects: 103
Study 7508331 — intervention group
Group type: COMPARATOR
Intervention: Prazosin (2 mg bid)
Number of subjects: 103
Study 3735627 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program discussing acceptable indications for x-ray pelvimetry
Number of subjects: 120
Study 3735627 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational program)
Number of subjects: 120
Study 31527463 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramedullary self-locked plates
Number of subjects: 24
Study 31527463 — intervention group
Group type: COMPARATOR
Intervention: Herbert screws
Number of subjects: 24
Study 28314639 — intervention group
Group type: EXPERIMENTAL
Intervention: Dark chocolate
Number of subjects: 0
Study 28314639 — intervention group
Group type: COMPARATOR
Intervention: Milk chocolate
Number of subjects: 0
Study 26211516 — intervention group
Group type: EXPERIMENTAL
Intervention: Shakuyakukanzoto (SKT) 2.5 g/day
Number of subjects: 0
Study 26211516 — intervention group
Group type: EXPERIMENTAL
Intervention: Shakuyakukanzoto (SKT) 5.0 g/day
Number of subjects: 0
Study 24072003 — intervention group
Group type: EXPERIMENTAL
Intervention: Trevo device
Number of subjects: 0
Study 24072003 — intervention group
Group type: COMPARATOR
Intervention: Merci device
Number of subjects: 0
Study 21669961 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg alagebrium twice daily
Number of subjects: 102
Study 21669961 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 18647853 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet PC self-administered questionnaires
Number of subjects: 153
Study 16151771 — intervention group
Group type: EXPERIMENTAL
Intervention: [123I]Mtr-TOCA
Number of subjects: 6
Study 16151771 — intervention group
Group type: COMPARATOR
Intervention: [111In]OC
Number of subjects: 6
Study 16151771 — intervention group
Group type: EXPERIMENTAL
Intervention: [123I]Mtr-TOCA and [111In]OC
Number of subjects: 6
Study 12932064 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 2.5 microg
Number of subjects: 80
Study 12932064 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 5.0 microg
Number of subjects: 80
Study 12932064 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 7.5 microg
Number of subjects: 80
Study 12932064 — intervention group
Group type: COMPARATOR
Intervention: No sufentanil (Control Group 1)
Number of subjects: 80
Study 10744202 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical dorzolamide 2% (Trusopt) three times daily for three days
Number of subjects: 62
Study 10744202 — intervention group
Group type: COMPARATOR
Intervention: Oral acetozolamide (Diazomide) 250 mg three times daily for three days
Number of subjects: 62
Study 8774390 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent intravenous 1 alpha(OH)D3 treatment for > 300 days
Number of subjects: 26
Study 8774390 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent oral 1 alpha(OH)D3 treatment for 100 days
Number of subjects: 26
Study 8774390 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinstatement of intermittent intravenous 1 alpha(OH)D3 treatment for another 100 days
Number of subjects: 26
Study 1727741 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 25 mg (b.i.d.)
Number of subjects: 18
Study 6653133 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol (500 mg) plus metoclopramide (5 mg)
Number of subjects: 39
Study 6653133 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol (500 mg) alone
Number of subjects: 39
Study 31843183 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided bone regeneration with particulate xenogenic bone substitutes
Number of subjects: 0
Study 31843183 — intervention group
Group type: COMPARATOR
Intervention: Guided bone regeneration with particulate xenogenic bone substitutes and autogenous block grafts
Number of subjects: 0
Study 30134971 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous methylprednisolone
Number of subjects: 30
Study 30134971 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 26350667 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous enoxaparin 30 mg b.i.d.
Number of subjects: 34
Study 23870610 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ticagrelor (400 mg daily) for 6 days followed by oral midazolam (7.5 mg)
Number of subjects: 28
Study 23870610 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous midazolam (2.5 mg) after ticagrelor (270 mg single dose, then 180 mg BID for 6 days)
Number of subjects: 28
Study 23870610 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 20689452 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (AO leg)
Number of subjects: 16
Study 20689452 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration
Number of subjects: 16
Study 19775041 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactated solution (Hartmann's solution; anions: chloride 109 mmol/l, lactate 29 mmol/l)
Number of subjects: 20
Study 19775041 — intervention group
Group type: COMPARATOR
Intervention: Chloride-only solution (Ringer's Injection; anions: chloride 152 mmol/l)
Number of subjects: 20
Study 17106320 — intervention group
Group type: EXPERIMENTAL
Intervention: A&D UB‐511 (UB‐512) device for self-measurement of blood pressure
Number of subjects: 85
Study 15561385 — intervention group
Group type: EXPERIMENTAL
Intervention: GW‐1000‐02 (Sativex), containing Delta(9)tetrahydrocannabinol (THC):cannabidiol (CBD) in an approximate 1:1 ratio
Number of subjects: 48
Study 15561385 — intervention group
Group type: EXPERIMENTAL
Intervention: GW‐2000‐02, containing primarily THC
Number of subjects: 48
Study 15561385 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 11403724 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel smoking system
Number of subjects: 32
Study 11403724 — intervention group
Group type: COMPARATOR
Intervention: Own brand of cigarettes
Number of subjects: 32
Study 11403724 — intervention group
Group type: COMPARATOR
Intervention: Marketed brand that was not their own
Number of subjects: 32
Study 11403724 — intervention group
Group type: COMPARATOR
Intervention: De-nicotinized tobacco cigarettes
Number of subjects: 32
Study 8213583 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg once daily at bedtime
Number of subjects: 1062
Study 8213583 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1062
Study 2485066 — intervention group
Group type: EXPERIMENTAL
Intervention: H142 at 1.0 mg/kg/h
Number of subjects: 9
Study 2485066 — intervention group
Group type: EXPERIMENTAL
Intervention: H142 at 2.5 mg/kg/h
Number of subjects: 9
Study 2485066 — intervention group
Group type: COMPARATOR
Intervention: 5% dextrose (control)
Number of subjects: 9
Study 2485066 — intervention group
Group type: EXPERIMENTAL
Intervention: H142 (both doses)
Number of subjects: 9
Study 28749571 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous L-ornithine L-aspartate (LOLA), 30g daily for 5 days
Number of subjects: 193
Study 28749571 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study 27273854 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery (ERAS) programme
Number of subjects: 0
Study 27273854 — intervention group
Group type: COMPARATOR
Intervention: Standard conventional care pathway
Number of subjects: 0
Study 27273854 — intervention group
Group type: COMPARATOR
Intervention: Both ERAS and Standard care
Number of subjects: 0
Study 25803546 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Number of subjects: 98
Study 25803546 — intervention group
Group type: COMPARATOR
Intervention: Control capsules
Number of subjects: 98
Study 23593611 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a plus ribavirin therapy (Clinical Trial group)
Number of subjects: 272
Study 23593611 — intervention group
Group type: COMPARATOR
Intervention: peginterferon alfa-2a plus ribavirin therapy (Cohort group)
Number of subjects: 272
Study 19932589 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexrazoxane
Number of subjects: 20
Study 19932589 — intervention group
Group type: COMPARATOR
Intervention: ProMECE-CytaBOM infusion
Number of subjects: 20
Study 19932589 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexrazoxane supplementation
Number of subjects: 20
Study 18442542 — intervention group
Group type: EXPERIMENTAL
Intervention: PAS-Port system
Number of subjects: 99
Study 18442542 — intervention group
Group type: COMPARATOR
Intervention: Control group (hand-sewn technique)
Number of subjects: 99
Study 18442542 — intervention group
Group type: EXPERIMENTAL
Intervention: PAS-Port group
Number of subjects: 99
Study 18442542 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 99
Study 16799778 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TNFalpha therapy
Number of subjects: 9
Study 12520631 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine CR 150 mg bid
Number of subjects: 0
Study 12520631 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine CR 300 mg daily
Number of subjects: 0
Study 12520631 — intervention group
Group type: COMPARATOR
Intervention: Nizatidine IR 150 mg bid
Number of subjects: 0
Study 10644535 — intervention group
Group type: EXPERIMENTAL
Intervention: Low energy availability (A = 45 kcal kg LBM(‐1) x day(‐1))
Number of subjects: 16
Study 10644535 — intervention group
Group type: COMPARATOR
Intervention: Exercise stress (E = 30 kcal x kg LBM(‐1) x day(‐1))
Number of subjects: 16
Study 9127064 — intervention group
Group type: COMPARATOR
Intervention: Prone positioner
Number of subjects: 20
Study 7934692 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative iliohypogastric ilioinguinal nerve block (IINB) with 0.25% bupivacaine at 1 mg/Kg
Number of subjects: 30
Study 7934692 — intervention group
Group type: COMPARATOR
Intervention: Postoperative iliohypogastric ilioinguinal nerve block (IINB) with 0.25% bupivacaine at 1 mg/Kg
Number of subjects: 30
Study 7934692 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group B)
Number of subjects: 30
Study 3782654 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxepin
Number of subjects: 16
Study 3782654 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 29912077 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined weight training program (CT) using speed-lifts and plyometrics
Number of subjects: 28
Study 29912077 — intervention group
Group type: COMPARATOR
Intervention: Flexible barbell (FB) training with a fixed mass of 56.82 kg
Number of subjects: 28
Study 29912077 — intervention group
Group type: EXPERIMENTAL
Intervention: Margaria-Kalamen stair power test
Number of subjects: 28
Study 27573565 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone (MNTX)
Number of subjects: 229
Study 27573565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 229
Study 27573565 — intervention group
Group type: EXPERIMENTAL
Intervention: Response to MNTX treatment
Number of subjects: 229
Study 27573565 — intervention group
Group type: COMPARATOR
Intervention: No response to MNTX treatment
Number of subjects: 229
Study 27573565 — intervention group
Group type: EXPERIMENTAL
Intervention: MNTX
Number of subjects: 229
Study 27573565 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin ≥3.5
Number of subjects: 229
Study 27573565 — intervention group
Group type: COMPARATOR
Intervention: MNTX vs. placebo in patients with advanced illness other than cancer
Number of subjects: 229
Study 24679062 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (200 mg before surgery, 100 mg daily for 30 days in initiation stratum; 100 mg daily for 7 days in continuation stratum)
Number of subjects: 10010
Study 24679062 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10010
Study 24679062 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 10010
Study 22489519 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-early application with intermittent pneumatic compression (IPC) starting 3 days before operation
Number of subjects: 80
Study 22489519 — intervention group
Group type: COMPARATOR
Intervention: Postoperative application with intermittent pneumatic compression (IPC) starting on the day of operation
Number of subjects: 80
Study 22489519 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-early application with IPC
Number of subjects: 80
Study 22489519 — intervention group
Group type: COMPARATOR
Intervention: Postoperative application with IPC
Number of subjects: 80
Study 20146569 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperthermia treatment planning guided steering (HGS) during the second and fourth treatments
Number of subjects: 36
Study 20146569 — intervention group
Group type: COMPARATOR
Intervention: Rotterdam Empirical Steering Guidelines (RESG) during the second and third treatments
Number of subjects: 36
Study 20146569 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperthermia treatment planning guided steering (HGS) during the fourth and fifth treatments
Number of subjects: 36
Study 20146569 — intervention group
Group type: COMPARATOR
Intervention: Rotterdam Empirical Steering Guidelines (RESG) during the fourth and fifth treatments
Number of subjects: 36
Study 18272794 — intervention group
Group type: EXPERIMENTAL
Intervention: EE + LLLT
Number of subjects: 52
Study 18272794 — intervention group
Group type: COMPARATOR
Intervention: EE + placebo LLLT
Number of subjects: 52
Study 15918381 — intervention group
Group type: EXPERIMENTAL
Intervention: ProSeal laryngeal mask airway (PLMA)
Number of subjects: 90
Study 15918381 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal tube S (LTS)
Number of subjects: 90
Study 15918381 — intervention group
Group type: COMPARATOR
Intervention: Oesophageal‐tracheal combitube (OTC)
Number of subjects: 90
Study 12875680 — intervention group
Group type: EXPERIMENTAL
Intervention: HBIG (200 IU or 400 IU intramuscularly at 3, 2 and 1 month before delivery)
Number of subjects: 980
Study 12875680 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific treatment)
Number of subjects: 980
Study 10597557 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (40 micrograms.kg-1)
Number of subjects: 120
Study 10597557 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 120
Study 8682484 — intervention group
Group type: EXPERIMENTAL
Intervention: Pefloxacin (800mg per day) plus Klindamicin (2,400mg per day)
Number of subjects: 75
Study 8682484 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin (4,000mg per day)
Number of subjects: 75
Study 8682484 — intervention group
Group type: EXPERIMENTAL
Intervention: Pefloxacin plus Klindamicin
Number of subjects: 75
Study 8682484 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin
Number of subjects: 75
Study 1357350 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracervical lignocaine
Number of subjects: 0
Study 3899772 — intervention group
Group type: EXPERIMENTAL
Intervention: Penbutolol 40 mg once a day
Number of subjects: 17
Study 3899772 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenylamine 60 mg t.i.d.
Number of subjects: 17
Study 31332025 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment combined with breathing exercise rehabilitation
Number of subjects: 64
Study 31332025 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 64
Study 29501470 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 session/week of group exercise (30-minute sessions)
Number of subjects: 27
Study 29501470 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 sessions/week of group exercise (30-minute sessions)
Number of subjects: 27
Study 25809790 — intervention group
Group type: EXPERIMENTAL
Intervention: Couple-based treatment with emphasis on 'we' language
Number of subjects: 188
Study 25809790 — intervention group
Group type: EXPERIMENTAL
Intervention: Couple-based treatment with emphasis on 'you' and 'I' language
Number of subjects: 188
Study 24742032 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored multi-faceted improvement implementation programme
Number of subjects: 124
Study 24742032 — intervention group
Group type: COMPARATOR
Intervention: National guideline and feedback letters (control group)
Number of subjects: 124
Study 22080174 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.75 μg H5N1 haemagglutinin antigen
Number of subjects: 110
Study 22080174 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 μg H5N1 haemagglutinin antigen
Number of subjects: 110